Lukkarinen O, Kontturi M
Department of Surgery, Oulu University Central Hospital, Finland.
Scand J Urol Nephrol Suppl. 1988;110:109-12.
We treated 38 patients with newly diagnosed advanced prostatic cancer with monthly injections of a long acting depot preparation of a luteinizing hormone-releasing hormone superagonist (Zoladex depot). After 6 months' treatment 10% of the patients had complete objective regression, 77% had partial objective regression, 3% stable disease and 10% had objective progression. The LHRH analogue does not have the metabolic side effects of oestrogens. Depot luteinizing hormone-releasing hormone analogue may well become a preferred alternative for patients with advanced prostatic cancer.
我们对38例新诊断的晚期前列腺癌患者进行治疗，每月注射一次长效促黄体生成素释放激素超级激动剂（诺雷德长效注射剂）的长效储存制剂。治疗6个月后，10%的患者出现完全客观缓解，77%的患者出现部分客观缓解，3%病情稳定，10%出现客观进展。促黄体生成素释放激素类似物没有雌激素的代谢副作用。长效促黄体生成素释放激素类似物很可能成为晚期前列腺癌患者的首选替代药物。
